CoLucid Pharmaceuticals, Inc. 4
4 · CoLucid Pharmaceuticals, Inc. · Filed Dec 1, 2016
Insider Transaction Report
Form 4
Dallas Matthew D
Chief Financial Officer
Transactions
- Sale
Common Stock
2016-12-01$35.17/sh−1,473$51,801→ 41,601 total
Footnotes (3)
- [F1]Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Dallas on August 15, 2016. One purpose of the plan is to sell shares of common stock acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan.
- [F2]Represents the sale of 1,473 shares in multiple transactions, ranging in price from $35.00 to $35.45 per share, resulting in a weighted average sale price of $35.1671. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- [F3]Includes 5,574 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through November 30, 2016.